Comment from Endocrine Technology LLC

Summary: Endocrine Technology, LLC, a biotechnology company, supports the proposed pilot program for AI-enabled optimization of early-phase clinical trials. The company argues that current drug discovery and clinical trial processes suffer from significant "blind spots" regarding fluid immunity and Factor H/D, and they believe their AI-enabled technology can address these lapses to improve efficacy and reduce costs.